Lentiviral vector interactions with the host cell

Borsotti, Chiara; Borroni, Ester; Follenzi, Antonia

doi:10.1016/j.coviro.2016.08.016

Cited by 17 publications

(21 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLR7, the PRR that senses single-stranded RNA molecules in endosomes, and TLR9 contribute to induction of T1 IFN. 118,119 It has been proposed that VSV-G protein-pseudotyped LV vectors may contain tubulovesicular structures with DNA fragments that promote TLR9 signaling. 120 The strength of TLR7 and TLR9 downstream signaling is in part regulated by the mammalian target of rapamycin (mTOR) pathway.…”

Section: Immunotoxicitiesmentioning

confidence: 99%

Immune Responses to Viral Gene Therapy Vectors

et al. 2020

View full text Add to dashboard Cite

Several viral vector-based gene therapy drugs have now received marketing approval. A much larger number of additional viral vectors are in various stages of clinical trials for the treatment of genetic and acquired diseases, with many more in pre-clinical testing. Efficiency of gene transfer and ability to provide long-term therapy make these vector systems very attractive. In fact, viral vector gene therapy has been able to treat or even cure diseases for which there had been no or only suboptimal treatments. However, innate and adaptive immune responses to these vectors and their transgene products constitute substantial hurdles to clinical development and wider use in patients. This review provides an overview of the type of immune responses that have been documented in animal models and in humans who received gene transfer with one of three widely tested vector systems, namely adenoviral, lentiviral, or adeno-associated viral vectors. Particular emphasis is given to mechanisms leading to immune responses, efforts to reduce vector immunogenicity, and potential solutions to the problems. At the same time, we point out gaps in our knowledge that should to be filled and problems that need to be addressed going forward.

show abstract

Section: Immunotoxicitiesmentioning

confidence: 99%

Immune Responses to Viral Gene Therapy Vectors

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Once PRRs recognize PAMPs, they induce a type 1-interferon response, which converts macrophages to a prophagocytic state. This leads to release of pro-inflammatory cytokines and, eventually, destruction of the virus [78]. Whether these mechanisms are also found in microglia is still under investigation, but several studies have suggested parallels [79].…”

Section: Challenges On the Path To Successful Microglial Transductionmentioning

confidence: 99%

Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges

Maes

Colombo

Schulz

et al. 2019

Neuroscience Letters

103

View full text Add to dashboard Cite

show abstract

“…Lentivirus as a vector can result in long-lasting changes, but has been associated with a risk of neoplasia. It is likely that in the future, improved understanding of host-vector interactions may allow safe use of lentivirus vectors [51]. Tbx is a gene that is important for SAN specification during early development.…”

Section: Gene-based Approachesmentioning

confidence: 99%

Biological Pacemakers – A Review

Gunasekaran

Selvaraj

2018

ijcp

View full text Add to dashboard Cite

Slow heart rates, due to sinus node disease or atrioventricular conduction block, are a significant problem for many patients. Currently, these patients are treated with electronic pacemakers, which provide effective therapy, but are also associated with many problems. Use of biological pacemakers is an attractive solution to these problems. Approaches for the creation of such pacemakers include either the injection of cells that have pacemaker activity (cell-based approach) or modification of cells in the heart to induce pacemaker activity by delivering genes (gene-based approach). This article reviews the progress in the development of biological pacemakers.

show abstract

Lentiviral vector interactions with the host cell

Cited by 17 publications

References 73 publications

Immune Responses to Viral Gene Therapy Vectors

Immune Responses to Viral Gene Therapy Vectors

Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges

Biological Pacemakers – A Review

Contact Info

Product

Resources

About